Aranesp's life signs

It's not often that everyone is happy with a study that misses its primary endpoint, but that's exactly what happened last week, when Amgen Inc. reported top-line results from Study 145 of Aranesp darbepoetin alfa in advanced small cell lung cancer. The key was that there were not